Adjuvant interferon gamma in patients with drug - Resistant pulmonary tuberculosis: A pilot study

BMC Infectious Diseases

Volumn 4, Issue , 2004, Pages

  Suárez Méndez, Roberto ^a   Garía García, Idrian ^b   Fernández Olivera, Norma ^a   Valdés Quintana, Magalys ^a   Milanés Virelles, María T ^a   Carbonell, Dalia ^a   Valenzuela Silva, Carmen M ^b   López Saura, Pedro A ^b  

^a Hospital Neumologico Benefico Juridico   (Cuba)

^b Center for Biological Research Cuba   (Cuba)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; CIPROFLOXACIN; ETHAMBUTOL; ETHIONAMIDE; HEBERON GAMMA R; IMMUNOLOGICAL ADJUVANT; ISONIAZID; KANAMYCIN; PYRAZINAMIDE; RECOMBINANT GAMMA INTERFERON; RIFAMPICIN; STREPTOMYCIN; GAMMA INTERFERON; RECOMBINANT PROTEIN; TUBERCULOSTATIC AGENT;

ACID FAST BACTERIUM; ADULT; ANTIBIOTIC SENSITIVITY; ARTHRALGIA; ARTICLE; BODY MASS; CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CUBA; DATA ANALYSIS; DRUG MECHANISM; DRUG TOLERABILITY; FEMALE; FEVER; HOSPITAL PATIENT; HUMAN; LUNG TUBERCULOSIS; MALE; MULTIDRUG RESISTANCE; OPEN STUDY; OUTCOMES RESEARCH; PILOT STUDY; PRACTICE GUIDELINE; SPUTUM ANALYSIS; SPUTUM CULTURE; SPUTUM SMEAR; THORAX RADIOGRAPHY; WORLD HEALTH ORGANIZATION; ANTIBIOTIC RESISTANCE; DRUG COMBINATION; DRUG EFFECT; FOLLOW UP; ISOLATION AND PURIFICATION; MICROBIOLOGY; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; RADIOGRAPHY; SPUTUM; TREATMENT OUTCOME;

ADJUVANTS, IMMUNOLOGIC; ADULT; AMIKACIN; ANTITUBERCULAR AGENTS; CIPROFLOXACIN; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; ETHAMBUTOL; ETHIONAMIDE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERFERON-GAMMA; KANAMYCIN; MALE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; PILOT PROJECTS; PYRAZINAMIDE; RECOMBINANT PROTEINS; RIFAMPIN; SPUTUM; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY;

EID: 10144246651     PISSN: 14712334     EISSN: None     Source Type: Journal    
DOI: 10.1186/1471-2334-4-44     Document Type: Article

References (42)

1. Raviglione MC, Snider DE, Kochi A: Global epidemiology of tuberculosis: prevalence and mortality of a worldwide. JAMA 1995, 273:220-6.
2. Tuberculosis. WHO information, Fact Sheet No 4 2000.
3. Murray CJ, Lopez AD: Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet 1997, 349:1269-76.
4. Iseman MD: Tuberculosis. In Cecil Textbook of Medicine, Section Diseases due to Micobacteria 2 1 2000:1724-32.
5. Ellner JJ: Multidrug-resistant tuberculosis. Adv Intern Med 1995, 40:155-96.
6. Park M, Davis AL, Schluger N, Cohen H, Ron WN: Outcome of MDR-TB patients 1983-1993: prolonged survival with appropriate therapy. Am J Respir Crit Care Med 1996, 153:317-24.
7. Pablos-Mendez A, Raviglione MC, Laszlo A, Binkin N, Rieder HL, Bustreo F, Cohn DL, Lambregts-van Weezenbeek CS, Kim SJ, Chaulet P, Nunn P: Global surveillance for antituberculosis-drug resistance, 1994-1997. World Health Organization - International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. N Engl J Med 1998, 338:1641-9.
8. Schluger NW, Harkin TJ, Rom WN: Principles of therapy of tuberculosis in the modern era. In In: Tuberculosis Edited by: Rom, Garay. Little Brown, New York; 1996:751-9.
9. Schraufnagel DE: Tuberculosis treatment for the beginning of the next century. Int J Tuberc Lung Dis 1999, 3:651-62.
10. Galling JL, Farber JM, Holland SM, Nutman TB: Inteferon-γ in the management of infectious diseases. Ann Intern Med 1995, 123:216-24.
11. Holland SM: Therapy of mycobacterial infections. Res Immunol 1996, 147:572-81.
12. Bermudez LE, Inderlied C, Young LS: Stimulation with cytokines enhances penetration of azithromicin into human macrophages. Antimicrob Agents Chemother 1991, 35:2625-9.
13. Bonecini-Almeida MG, Chitale S, Boutsikakis I, Geng J, Doo H, He S, Ho JL: Induction of in vitro human macrophage anti-mycobacterium tuberculosis activity: Requirement for IFNγ and primed lymphocytes. J Immunol 1998, 160:4490-9.
14. Murray HW: Interferon-γ and host antimicrobial defense: current and future clinical applications. Am J Med 1994, 97: 59-67.
15. Cooper MA, Dalton DK, Stewart TA: Disseminated tuberculosis in interferon γ gene-disrupted mice. J Exptl Med 1993, 178:2243-7.
16. Levin M, Newport M: Unraveling the genetic basis of susceptibility to mycobacterial infection. J Pathol 1997, 181:5-7.
17. Dormand SE, Holland SM: Mutation in the signal-transducing chain of the interferon-γ receptor and susceptibility to mycobacterial infections. J Clin Invest 1998, 101:2364-9.
18. Sempowski GD, Derdak S, Phipps RP: Interleukin 4 and interferon gamma discordance regulate collagen biosynthesis by functionally distinct lung fibroblast subsets. J Cell Physiol 1996, 167:290-6.
19. Harrop AR, Ghahary A, Scott PG, Forsyth N, Friedland A, Tredget EE: Effect of γ interferon on cell proliferation, collagen production and procollagen mRNA expression in hypertrophic scar fibroblast in vitro. J Surg Res 1995, 58:471-7.
20. Gurujeyalakshmi G, Giri SN: Molecular mechanisms of antifibrotic effect of interferon gamma in bleomycin model of lung fibrosis. Down regulation of TGF-beta and procollagen I and III gene expression.Exp Lung Res 1995, 21:791-808.
21. Canetti G, Rist N, Grosset J: Measurement of sensitivity of the tuberculous bacillus to antibacillary drugs by the method of proportions. Methodology, resistance criteria, results and interpretation. Rev Tuberc Pneumol (Paris) 1963, 27: 17-72.
22. Crofton J, Chaulet P: Guidelines for the management of Drug-Resistant Tuberculosis. Word Health Organization 1997.
23. Ministry of Public Health of Cuba: Anuario Estadístico de Salud. 2002 [http://www.sld.cu/servicios/estadisticas.html].
24. Ziesche R, Hofbauer E, Wittmann K, Petkov V, Block LH: A preliminary study of long-term treatment with interferon gamma-1b and low dose prednisolone in patients with idiopathic pulmonary fibrosis. N Engl J Med 1999, 341:1264-9.
25. Vial T, Descotes J: Clinical toxicity of the interferons. Drug safety 1994, 10:115-50.
26. Flynn JL, Chan J, Triebold KJ, Dalton DK, Stewart TA, Bloom BR: An essential role for interferon γ in resistance to Mycobacterium tuberculosis . J Exptl Med 1993, 178:2249-54.
27. Dalton DK, Pitts-Meek S, Keshav S, Figari IS, Bradley A, Stewart TA: Multiple defects of immune cell function in mice with disrupted interferon-gamma genes. Science 1993, 259: 739-42.
28. Barnes PF, Lu S, Abrams JS, Wang E, Yamamura M, Modlin RL: Cytokine production at the site of disease in human tuberculosis. Infect Immun 1993, 61:3482-9.
29. Bienkowski RS, Gotkin MG: Control of collagen deposition in mammalian lung. Proc Soc Exp Biol Med 1995, 209:118-40.
30. Broekelmann TJ, Limper AH, Colby TV, McDonald JA: Transforming growth factor beta is present at sites of extracellular matrix gene expression in human pulmonary fibrosis. Proc Natl Acad Sci USA 1991, 88:6642-7.
31. Khalil N, Whitman C, Zuo L, Danielpour D, Greenberg A: Regulation of alveolar macrophage transforming growth factor beta secretion by corticosteroids in bleomycin-induced pulmonary inflammation in the rat. J Clin Invest 1993, 92:1812-17.
32. Limper AH, Colby TV, Asakura S, Roche PC, DeRemee RA: Immunohistochemical granulomas of pulmonary sarcoidosis. Am J Respir Crit Care Med 1994, 149:197-204.
33. Jouanguy E, Lamhamedi-Cherradi S, Altare F, Fondaneche MC, Tuerlinckx D, Blanche S, Emile JF, Gaillard JL, Schreiber R, Levin M, Fischer A, Hivroz C, Casanova JL: Partial interferon-γ-receptor 1 deficiency in a child with tuberculoid bacillus Calmette-Guerin infection and a sibling with clinical tuberculosis. J Clin Invest 1997, 100:2658-64.
34. Levin M, Newport M: Understanding the genetic basis of susceptibility to mycobacterial infection. Proc Assoc Am Physicians 1999, 111:308-312.
35. Lammas DA, Drysdale P, Ben-Smith A, Girdlestone J, Edgar D, Kumararatne DS: Diagnosis of defects in the type 1 cytokine pathway. Microbes and Infect 2000, 2:1567-78.
36. Raad I, Hachem R, Leeds N, Sawaya R, Salem Z, Atweh S: Use of adjunctive treatment with interferon γ in an immunocompromised patient who had refractory multidrug-resistant tuberculosis of the brain. Clin Infect Dis 1996, 22:572-4.
37. Jaffe HA, Buhl R, Mastrangeli A, Holroyd KJ, Saltini C, Czerski D, Jaffe HS, Kramer S, Sherwin S, Crystal RG: Organ specific cytokine therapy: Local activation of mononuclear phagocytes by delivery of an aerosol of recombinant interferon gamma to the human lung. J Clin Invest 1991, 88:297-302.
38. Condos R, Rom WN, Schulger NW: Treatment of multidrug-resistant tuberculosis with interferon γ via aerosol. Lancet 1997, 349:1513-5.
39. Chatte G, Panteix G, Perrin-Fayolle M, Pacheco Y: Aerosolized interferon gamma for Mycobacterium avium complex lung disease. Amer J Respir Crit Care Med 1995, 152:1094-6.
40. Holland SM, Eisenstein EM, Kuhns DB, Turner ML, Fleisher TA, Strober W, Gallin JI: Treatment of refractory disseminated nontuberculous mycobacterial infection with interferon gamma. A preliminary report. N Engl J Med 1994, 330:1348-55.
41. Squires KE, Brown ST, Armstrong D, Murphy WF, Murray HW: Interferon gamma treatment for Mycobacterium aviumintracellulare complex bacillemia in patients with AIDS. J Infect Dis 1992, 166: 86-7.
42. Nathan CF, Kaplan G, Levis WR, Nusrat A, Witmer MD, Sherwin SA, Job CK, Horowitz CR, Steinman RM, Cohn ZA: Local and systemic effects of intradermal recombinant interferon-γ in patients with lepromatous leprosy. N Engl J Med 1986, 315:6-15.